{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T13:12:22Z","timestamp":1790341942005,"version":"4.1.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,2,26]],"date-time":"2022-02-26T00:00:00Z","timestamp":1645833600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,2,26]],"date-time":"2022-02-26T00:00:00Z","timestamp":1645833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s11912-022-01218-y","type":"journal-article","created":{"date-parts":[[2022,2,26]],"date-time":"2022-02-26T08:02:34Z","timestamp":1645862554000},"page":"651-658","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":66,"title":["New Checkpoint Inhibitors on the Road: Targeting TIM-3 in Solid Tumors"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0991-1217","authenticated-orcid":false,"given":"Ana Luiza","family":"Gomes de Morais","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Cerd\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9366-8602","authenticated-orcid":false,"given":"Maria","family":"de Miguel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,26]]},"reference":[{"key":"1218_CR1","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.cell.2019.01.008","volume":"176","author":"MF Sanmamed","year":"2019","unstructured":"Sanmamed MF, Chen L. A paradigm shift in cancer immunotherapy: from enhancement to normalization. Cell. 2019;176:677.","journal-title":"Cell"},{"key":"1218_CR2","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41573-018-0006-z","volume":"18","author":"RS Riley","year":"2019","unstructured":"Riley RS, June CH, Langer R, Mitchell MJ. Delivery technologies for cancer immunotherapy. Nat Rev Drug Discov. 2019;18:175\u201396. https:\/\/doi.org\/10.1038\/s41573-018-0006-z.","journal-title":"Nat Rev Drug Discov."},{"key":"1218_CR3","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.cell.2009.06.036","volume":"138","author":"HW Virgin","year":"2009","unstructured":"Virgin HW, Wherry EJ, Ahmed R. Redefining chronic viral infection. Cell. 2009;138:30\u201350. https:\/\/doi.org\/10.1016\/j.cell.2009.06.036.","journal-title":"Cell"},{"key":"1218_CR4","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/ni.2035","volume":"12","author":"EJ Wherry","year":"2011","unstructured":"Wherry EJ. T cell exhaustion. Nat Immunol. 2011;12:492\u20139. https:\/\/doi.org\/10.1038\/ni.2035.","journal-title":"Nat Immunol."},{"key":"1218_CR5","doi-asserted-by":"publisher","first-page":"250","DOI":"10.20517\/2394-4722.2017.41","volume":"3","author":"SJ Oiseth","year":"2017","unstructured":"Oiseth SJ. Aziz MS Cancer immunotherapy: a brief review of the history, possibilities, and challenges ahead. J Cancer Metastasis Treat. 2017;3:250. https:\/\/doi.org\/10.20517\/2394-4722.2017.41.","journal-title":"J Cancer Metastasis Treat."},{"key":"1218_CR6","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.3389\/fonc.2020.01288","volume":"10","author":"S Qin","year":"2020","unstructured":"Qin S, Dong B, Yi M, et al. Prognostic values of TIM-3 expression in patients with solid tumors: a meta-analysis and database evaluation. Front Oncol. 2020;10:1288. https:\/\/doi.org\/10.3389\/fonc.2020.01288.","journal-title":"Front Oncol."},{"key":"1218_CR7","doi-asserted-by":"publisher","first-page":"9122","DOI":"10.1128\/JVI.00639-09","volume":"83","author":"L Golden-Mason","year":"2009","unstructured":"Golden-Mason L, Palmer BE, Kassam N, et al. Negative immune regulator Tim-3 is overexpressed on T cells in hepatitis C virus infection and its blockade rescues dysfunctional CD4+ and CD8+ T cells. J Virol. 2009;83:9122\u201330. https:\/\/doi.org\/10.1128\/JVI.00639-09.","journal-title":"J Virol."},{"key":"1218_CR8","doi-asserted-by":"publisher","first-page":"20592","DOI":"10.18632\/oncotarget.4112","volume":"6","author":"B Xu","year":"2015","unstructured":"Xu B, Yuan L, Gao Q, et al. Circulating and tumor-infiltrating Tim-3 in patients with colorectal cancer. Oncotarget. 2015;6:20592\u2013603. https:\/\/doi.org\/10.18632\/oncotarget.4112.","journal-title":"Oncotarget"},{"key":"1218_CR9","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1038\/ni987","volume":"4","author":"A S\u00e1nchez-Fueyo","year":"2003","unstructured":"S\u00e1nchez-Fueyo A, Tian J, Picarella D, et al. Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance. Nat Immunol. 2003;4:1093\u2013101. https:\/\/doi.org\/10.1038\/ni987.","journal-title":"Nat Immunol."},{"key":"1218_CR10","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1038\/ni988","volume":"4","author":"CA Sabatos","year":"2003","unstructured":"Sabatos CA, Chakravarti S, Cha E, et al. Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. Nat Immunol. 2003;4:1102\u201310. https:\/\/doi.org\/10.1038\/ni988.","journal-title":"Nat Immunol."},{"key":"1218_CR11","doi-asserted-by":"publisher","first-page":"4522","DOI":"10.18632\/oncotarget.6608","volume":"7","author":"S Hervas-Stubbs","year":"2016","unstructured":"Hervas-Stubbs S, Soldevilla MM, Villanueva H, et al. Identification of TIM3 2\u2019-fluoro oligonucleotide aptamer by HT-SELEX for cancer immunotherapy. Oncotarget. 2016;7:4522\u201330. https:\/\/doi.org\/10.18632\/oncotarget.6608.","journal-title":"Oncotarget"},{"key":"1218_CR12","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.4049\/jimmunol.1400557","volume":"193","author":"RL Ferris","year":"2014","unstructured":"Ferris RL, Lu B, Kane L, et al. Too much of a good thing? Tim-3 and TCR signaling in T cell exhaustion. J Immunol. 2014;193:1525\u201330. https:\/\/doi.org\/10.4049\/jimmunol.1400557.","journal-title":"J Immunol."},{"key":"1218_CR13","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1038\/ni739","volume":"2","author":"JJ McIntire","year":"2001","unstructured":"McIntire JJ, Umetsu SE, Akbari O, et al. Identification of Tapr (an airway hyperreactivity regulatory locus) and the linked Tim gene family. Nat Immunol. 2001;2:1109\u201316. https:\/\/doi.org\/10.1038\/ni739.","journal-title":"Nat Immunol."},{"key":"1218_CR14","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/imr.12520","volume":"276","author":"M Das","year":"2017","unstructured":"Das M, Zhu C, Kuchroo VK. Tim-3 and its role in regulating anti-tumor immunity. Immunol Rev. 2017;276:97\u2013111. https:\/\/doi.org\/10.1111\/imr.12520.","journal-title":"Immunol Rev."},{"issue":"F1000 Faculty R","key":"1218_CR15","doi-asserted-by":"publisher","first-page":"316","DOI":"10.12688\/f1000research.13446.1","volume":"7","author":"H Banerjee","year":"2018","unstructured":"Banerjee H, Kane LP. Immune regulation by Tim-3 [version 1; peer review: 2 approved]. F1000Research. 2018;7(F1000 Faculty Rev):316. https:\/\/doi.org\/10.12688\/f1000research.13446.1.","journal-title":"F1000Research."},{"key":"1218_CR16","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/415536a","volume":"415","author":"L Monney","year":"2002","unstructured":"Monney L, Sabatos CA, Gaglia JL, et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature. 2002;415:536\u201341. https:\/\/doi.org\/10.1038\/415536a.","journal-title":"Nature"},{"key":"1218_CR17","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1182\/bloodadvances.2018028340","volume":"3","author":"C Polprasert","year":"2019","unstructured":"Polprasert C, Takeuchi Y, Kakiuchi N, et al. Frequent germline mutations of HAVCR2 in sporadic subcutaneous panniculitis-like T-cell lymphoma. Blood Adv. 2019;3:588\u201395. https:\/\/doi.org\/10.1182\/bloodadvances.2018028340.","journal-title":"Blood Adv"},{"key":"1218_CR18","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1038\/s41588-018-0251-4","volume":"50","author":"T Gayden","year":"2018","unstructured":"Gayden T, Sepulveda FE, Khuong-Quang D-A, et al. Germline HAVCR2 mutations altering TIM-3 characterize subcutaneous panniculitis-like T cell lymphomas with hemophagocytic lymphohistiocytic syndrome. Nat Genet. 2018;50:1650\u20137. https:\/\/doi.org\/10.1038\/s41588-018-0251-4.","journal-title":"Nat Genet"},{"key":"1218_CR19","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1038\/nm.2871","volume":"18","author":"M Rangachari","year":"2012","unstructured":"Rangachari M, Zhu C, Sakuishi K, et al. Bat3 promotes T cell responses and autoimmunity by repressing Tim-3\u2013mediated cell death and exhaustion. Nat Med. 2012;18:1394\u2013400. https:\/\/doi.org\/10.1038\/nm.2871.","journal-title":"Nat Med"},{"key":"1218_CR20","doi-asserted-by":"publisher","first-page":"782","DOI":"10.4049\/jimmunol.1302663","volume":"192","author":"KL Clayton","year":"2014","unstructured":"Clayton KL, Haaland MS, Douglas-Vail MB, et al. T Cell Ig and mucin domain\u2013containing protein 3 is recruited to the immune synapse, disrupts stable synapse formation, and associates with receptor phosphatases. J Immunol. 2014;192:782\u201391. https:\/\/doi.org\/10.4049\/jimmunol.1302663.","journal-title":"J Immunol."},{"key":"1218_CR21","doi-asserted-by":"publisher","first-page":"3963","DOI":"10.1128\/mcb.05297-11","volume":"31","author":"J Lee","year":"2011","unstructured":"Lee J, Su EW, Zhu C, et al. Phosphotyrosine-dependent coupling of Tim-3 to T-cell receptor signaling pathways. Mol Cell Biol. 2011;31:3963\u201374. https:\/\/doi.org\/10.1128\/mcb.05297-11.","journal-title":"Mol Cell Biol."},{"key":"1218_CR22","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1038\/ni1271","volume":"6","author":"C Zhu","year":"2005","unstructured":"Zhu C, Anderson AC, Schubart A, et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol. 2005;6:1245\u201352. https:\/\/doi.org\/10.1038\/ni1271.","journal-title":"Nat Immunol."},{"key":"1218_CR23","doi-asserted-by":"publisher","first-page":"5791","DOI":"10.1007\/s13277-015-3248-y","volume":"36","author":"H Fu","year":"2015","unstructured":"Fu H, Liu Y, Xu L, et al. Galectin-9 predicts postoperative recurrence and survival of patients with clear-cell renal cell carcinoma. Tumor Biol. 2015;36:5791\u20139. https:\/\/doi.org\/10.1007\/s13277-015-3248-y.","journal-title":"Tumor Biol."},{"issue":"9","key":"1218_CR24","doi-asserted-by":"publisher","first-page":"e107988","DOI":"10.1371\/journal.pone.0107988","volume":"9","author":"IA Schulkens","year":"2014","unstructured":"Schulkens IA, Heusschen R, Van Den Boogaart V, et al. Galectin expression profiling identifies galectin-1 and galectin-9\u03945 as prognostic factors in stage I\/II non-small cell lung cancer. PLoS ONE. 2014;9(9):e107988. https:\/\/doi.org\/10.1371\/journal.pone.0107988.","journal-title":"PLoS ONE"},{"key":"1218_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/2162402X.2016.1273309","volume":"6","author":"K Sideras","year":"2017","unstructured":"Sideras K, Biermann K, Verheij J, et al. PD-L1, Galectin-9 and CD8+ tumor-infiltrating lymphocytes are associated with survival in hepatocellular carcinoma. Oncoimmunology. 2017;6:1\u201311. https:\/\/doi.org\/10.1080\/2162402X.2016.1273309.","journal-title":"Oncoimmunology."},{"key":"1218_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0152599","volume":"11","author":"Y Wang","year":"2016","unstructured":"Wang Y, Sun J, Ma C, et al. Reduced expression of galectin-9 contributes to a poor outcome in colon cancer by inhibiting NK cell chemotaxis partially through the Rho\/ROCK1 signaling pathway. PLoS ONE. 2016;11:1\u201319. https:\/\/doi.org\/10.1371\/journal.pone.0152599.","journal-title":"PLoS ONE"},{"key":"1218_CR27","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1074\/jbc.274.1.335","volume":"274","author":"M Huber","year":"1999","unstructured":"Huber M, Izzi L, Grondin P, et al. The carboxyl-terminal region of biliary glycoprotein controls its tyrosine phosphorylation and association with protein-tyrosine phosphatases SHP-1 and SHP-2 in epithelial cells. J Biol Chem. 1999;274:335\u201344. https:\/\/doi.org\/10.1074\/jbc.274.1.335.","journal-title":"J Biol Chem."},{"key":"1218_CR28","doi-asserted-by":"publisher","first-page":"6537","DOI":"10.4049\/jimmunol.166.11.6537","volume":"166","author":"R Kammerer","year":"2001","unstructured":"Kammerer R, Stober D, Singer BB, et al. Carcinoembryonic antigen-related cell adhesion molecule 1 on murine dendritic cells is a potent regulator of T cell stimulation. J Immunol. 2001;166:6537\u201344. https:\/\/doi.org\/10.4049\/jimmunol.166.11.6537.","journal-title":"J Immunol."},{"key":"1218_CR29","doi-asserted-by":"publisher","first-page":"6726","DOI":"10.1182\/blood-2008-10-184556","volume":"113","author":"AK Horst","year":"2009","unstructured":"Horst AK, Bickert T, Brewig N, et al. CEACAM1+ myeloid cells control angiogenesis in inflammation. Blood. 2009;113:6726\u201336. https:\/\/doi.org\/10.1182\/blood-2008-10-184556.","journal-title":"Blood"},{"key":"1218_CR30","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1002\/eji.1830240622","volume":"24","author":"J-P Coutelier","year":"1994","unstructured":"Coutelier J-P, Godfraind C, Dveksler GS, et al. B lymphocyte and macrophage expression of carcinoembryonic antigen-related adhesion molecules that serve as receptors for murine coronavirus. Eur J Immunol. 1994;24:1383\u201390. https:\/\/doi.org\/10.1002\/eji.1830240622.","journal-title":"Eur J Immunol."},{"key":"1218_CR31","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1038\/sj.jid.5700616","volume":"127","author":"Z Wiener","year":"2007","unstructured":"Wiener Z, Kohalmi B, Pocza P, et al. TIM-3 is expressed in melanoma cells and is upregulated in TGF-beta stimulated mast cells. J Invest Dermatol. 2007;127:906\u201314. https:\/\/doi.org\/10.1038\/sj.jid.5700616.","journal-title":"J Invest Dermatol."},{"key":"1218_CR32","doi-asserted-by":"publisher","first-page":"702889","DOI":"10.3389\/fgene.2021.702889","volume":"12","author":"ALW Huskey","year":"2021","unstructured":"Huskey ALW, McNeely I, Merner ND. CEACAM gene family mutations associated with inherited breast cancer risk \u2013 a comparative oncology approach to discovery. Front Genet. 2021;12:702889. https:\/\/doi.org\/10.3389\/fgene.2021.702889.","journal-title":"Front Genet"},{"key":"1218_CR33","doi-asserted-by":"publisher","first-page":"5527","DOI":"10.1038\/sj.onc.1209541","volume":"25","author":"N Leung","year":"2006","unstructured":"Leung N, Turbide C, Olson M, et al. Deletion of the carcinoembryonic antigen-related cell adhesion molecule 1 (Ceacam1) gene contributes to colon tumor progression in a murine model of carcinogenesis. Oncogene. 2006;25:5527\u201336. https:\/\/doi.org\/10.1038\/sj.onc.1209541.","journal-title":"Oncogene"},{"key":"1218_CR34","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1146\/annurev.immunol.021908.132603","volume":"28","author":"GP Sims","year":"2010","unstructured":"Sims GP, Rowe DC, Rietdijk ST, et al. HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol. 2010;28:367\u201388. https:\/\/doi.org\/10.1146\/annurev.immunol.021908.132603.","journal-title":"Annu Rev Immunol."},{"issue":"9","key":"1218_CR35","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1038\/ni.2376","volume":"13","author":"S Chiba","year":"2012","unstructured":"Chiba S, Baghdadi M, Akiba H, Yoshiyama H, Kinoshita I, Dosaka-Akita H, Fujioka Y, Ohba Y, Gorman JV, Colgan JD, Hirashima M, Uede T, Takaoka A, Yagita H, Jinushi M. Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat Immunol. 2012;13(9):832\u201342. https:\/\/doi.org\/10.1038\/ni.2376.","journal-title":"Nat Immunol."},{"key":"1218_CR36","doi-asserted-by":"publisher","first-page":"3821","DOI":"10.1182\/blood-2008-10-185884.37.3737","volume":"113","author":"M Nakayama","year":"2009","unstructured":"Nakayama M, Akiba H, Takeda K, et al. Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation. Blood. 2009;113:3821\u201330. https:\/\/doi.org\/10.1182\/blood-2008-10-185884.37.3737.","journal-title":"Blood"},{"key":"1218_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2019.01594","volume":"10","author":"IM Yasinska","year":"2019","unstructured":"Yasinska IM, Sakhnevych SS, Pavlova L, et al. The TiM-3-galectin-9 pathway and its regulatory mechanisms in human breast cancer. Front Immunol. 2019;10:1\u201313. https:\/\/doi.org\/10.3389\/fimmu.2019.01594.","journal-title":"Front Immunol."},{"key":"1218_CR38","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1084\/jem.20100637","volume":"207","author":"J Fourcade","year":"2010","unstructured":"Fourcade J, Sun Z, Benallaoua M, et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med. 2010;207:2175\u201386. https:\/\/doi.org\/10.1084\/jem.20100637.","journal-title":"J Exp Med."},{"key":"1218_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0030676","volume":"7","author":"X Gao","year":"2012","unstructured":"Gao X, Zhu Y, Li G, et al. TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression. PLoS ONE. 2012;7:1\u20138. https:\/\/doi.org\/10.1371\/journal.pone.0030676.","journal-title":"PLoS ONE"},{"issue":"3","key":"1218_CR40","doi-asserted-by":"publisher","first-page":"e58006","DOI":"10.1371\/journal.pone.0058006","volume":"8","author":"J Yan","year":"2013","unstructured":"Yan J, Zhang Y, Zhang JP, et al. Tim-3 expression defines regulatory T cells in human tumors. PLoS ONE. 2013;8(3):e58006. https:\/\/doi.org\/10.1371\/journal.pone.0058006.","journal-title":"PLoS ONE"},{"key":"1218_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4161\/onci.23849","volume":"2","author":"K Sakuishi","year":"2013","unstructured":"Sakuishi K, Ngiow SF, Sullivan JM, et al. TIM3+FOXP3+ regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer. Oncoimmunology. 2013;2:1\u20139. https:\/\/doi.org\/10.4161\/onci.23849.","journal-title":"Oncoimmunology."},{"key":"1218_CR42","doi-asserted-by":"publisher","first-page":"490","DOI":"10.3892\/ol.2013.1410","volume":"6","author":"Y Shang","year":"2013","unstructured":"Shang Y, Li Z, Li H, et al. TIM-3 expression in human osteosarcoma: Correlation with the expression of epithelial-mesenchymal transition-specific biomarkers. Oncol Lett. 2013;6:490\u20134. https:\/\/doi.org\/10.3892\/ol.2013.1410.","journal-title":"Oncol Lett."},{"key":"1218_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0053834","volume":"8","author":"Y Cao","year":"2013","unstructured":"Cao Y, Zhou X, Huang X, et al. Tim-3 expression in cervical cancer promotes tumor metastasis. PLoS ONE. 2013;8:1\u20138. https:\/\/doi.org\/10.1371\/journal.pone.0053834.","journal-title":"PLoS ONE"},{"key":"1218_CR44","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1158\/2326-6066.CIR-14-0156","volume":"3","author":"Y Komohara","year":"2015","unstructured":"Komohara Y, Morita T, Annan DA, et al. The coordinated actions of TIM-3 on cancer and myeloid cells in the regulation of tumorigenicity and clinical prognosis in clear cell renal cell carcinomas. Cancer Immunol Res. 2015;3:999\u20131007. https:\/\/doi.org\/10.1158\/2326-6066.CIR-14-0156.","journal-title":"Cancer Immunol Res."},{"key":"1218_CR45","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1084\/jem.20090397","volume":"207","author":"X Huang","year":"2010","unstructured":"Huang X, Bai X, Cao Y, et al. Lymphoma endothelium preferentially expresses Tim-3 and facilitates the progression of lymphoma by mediating immune evasion. J Exp Med. 2010;207:505\u201320. https:\/\/doi.org\/10.1084\/jem.20090397.","journal-title":"J Exp Med."},{"key":"1218_CR46","doi-asserted-by":"publisher","first-page":"33823","DOI":"10.18632\/oncotarget.5257","volume":"6","author":"IG Silva","year":"2015","unstructured":"Silva IG, Gibbs BF, Bardelli M, et al. Differential expression and biochemical activity of the immune receptor Tim-3 in healthy and malignant human myeloid cells. Oncotarget. 2015;6:33823\u201333. https:\/\/doi.org\/10.18632\/oncotarget.5257.","journal-title":"Oncotarget"},{"issue":"12","key":"1218_CR47","doi-asserted-by":"publisher","first-page":"e81799","DOI":"10.1371\/journal.pone.0081799","volume":"8","author":"J Jiang","year":"2013","unstructured":"Jiang J, Jin MS, Kong F, et al. Decreased Galectin-9 and increased Tim-3 expression are related to poor prognosis in gastric cancer. PLoS ONE. 2013;8(12):e81799. https:\/\/doi.org\/10.1371\/journal.pone.0081799.","journal-title":"PLoS ONE"},{"key":"1218_CR48","first-page":"8018","volume":"8","author":"E Zhou","year":"2015","unstructured":"Zhou E, Huang Q, Wang J, et al. Up-regulation of Tim-3 is associated with poor prognosis of patients with colon cancer. Int J Clin Exp Pathol. 2015;8:8018\u201327.","journal-title":"Int J Clin Exp Pathol."},{"key":"1218_CR49","doi-asserted-by":"publisher","first-page":"31705","DOI":"10.18632\/oncotarget.15954","volume":"8","author":"Y Zhang","year":"2017","unstructured":"\u2022 Zhang Y, Cai P, Liang T, et al. TIM-3 is a potential prognostic marker for patients with solid tumors: a systematic review and meta-analysis. Oncotarget. 2017;8:31705\u201313. https:\/\/doi.org\/10.18632\/oncotarget.15954. Even though there were some prior communications with preliminary clinical results, this is the first publication evaluating an anti-TIM3 monoclonal antibody in patients.","journal-title":"Oncotarget"},{"issue":"3","key":"1218_CR50","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.ccell.2020.07.004","volume":"38","author":"M de Miguel","year":"2020","unstructured":"de Miguel M. Calvo E (2020) Clinical challenges of immune checkpoint inhibitors. Cancer Cell. 2020;38(3):326\u201333. https:\/\/doi.org\/10.1016\/j.ccell.2020.07.004.","journal-title":"Cancer Cell"},{"key":"1218_CR51","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/nejmoa1604958","volume":"375","author":"JM Zaretsky","year":"2016","unstructured":"Zaretsky JM, Garcia-Diaz A, Shin DS, et al. mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med. 2016;375:819\u201329. https:\/\/doi.org\/10.1056\/nejmoa1604958.","journal-title":"N Engl J Med."},{"key":"1218_CR52","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ymeth.2018.11.008","volume":"154","author":"C Klein","year":"2019","unstructured":"Klein C, Schaefer W, Regula JT, et al. Engineering therapeutic bispecific antibodies using CrossMab technology. Methods. 2019;154:21\u201331. https:\/\/doi.org\/10.1016\/j.ymeth.2018.11.008.","journal-title":"Methods"},{"key":"1218_CR53","doi-asserted-by":"publisher","first-page":"S102","DOI":"10.1016\/s0959-8049(16)32903-3","volume":"69","author":"A Murtaza","year":"2016","unstructured":"Murtaza A, Laken H, Da Silva CJ, et al. Discovery of TSR-022, a novel, potent anti-human TIM-3 therapeutic antibody. Eur J Cancer. 2016;69:S102. https:\/\/doi.org\/10.1016\/s0959-8049(16)32903-3.","journal-title":"Eur J Cancer."},{"key":"1218_CR54","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s40425-017-0284-8","volume":"5","author":"GJ Weiss","year":"2017","unstructured":"Weiss GJ, Luke JL, Falchook G, et al. A phase 1 study of TSR-022, an anti-TIM-3 monoclonal antibody, in patients (pts) with advanced solid tumors. J Immunother Cancer. 2017;5:78-Abst O13.","journal-title":"J Immunother Cancer."},{"key":"1218_CR55","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s40425-018-0425-8","volume":"6","author":"D Davar","year":"2018","unstructured":"Davar D, Boasberg P, Eroglu Z, Falchook G, Gainor J, Hamilton E, et al. A phase 1 study of TSR-022, an anti-TIM-3 monoclonal antibody, in combination with TSR-042 (anti-PD-1) in patients with colorectal cancer and post-PD-1 NSCLC and melanoma. J Immunother Cancer. 2018;6:107-108-Abst O21.","journal-title":"J Immunother Cancer."},{"key":"1218_CR56","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1158\/1078-0432.CCR-20-4405","volume":"27","author":"JJ Harding","year":"2021","unstructured":"\u2022 Harding JJ, Moreno V, Bang Y-J, et al. Blocking TIM-3 in Treatment-refractory advanced solid tumors: a phase Ia\/b study of LY3321367 with or without an anti-PD-L1 antibody. Clin Cancer Res. 2021;27:2168\u201378. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-4405. In this meta-analysis, TIM-3 was shown to be a prognostic factor associated to poor OS and a more advanced disease.","journal-title":"Clin Cancer Res."},{"key":"1218_CR57","doi-asserted-by":"publisher","unstructured":"Hollebecque A, Chung HC, de Miguel MJ, et al. Safety and antitumor activity of \u03b1-PD-L1 antibody as monotherapy or in combination with \u03b1-TIM-3 antibody in patients with microsatellite instability-high\/mismatch repair-deficient tumors. Clin Cancer Res clincanres.0261.2021. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-0261.","DOI":"10.1158\/1078-0432.CCR-21-0261"},{"key":"1218_CR58","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1200\/JCO.19.02107","volume":"38","author":"DT Le","year":"2020","unstructured":"Le DT, Kim TW, van Cutsem E, et al. Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability\u2013high\/mismatch repair\u2013deficient metastatic colorectal cancer: KEYNOTE-164. J Clin Oncol. 2020;38:11\u20139. https:\/\/doi.org\/10.1200\/JCO.19.02107.","journal-title":"J Clin Oncol."},{"issue":"1","key":"1218_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO.19.02105","volume":"1;38","author":"A Marabelle","year":"2020","unstructured":"Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2020;1;38(1):1\u201310. https:\/\/doi.org\/10.1200\/JCO.19.02105.","journal-title":"J Clin Oncol."},{"key":"1218_CR60","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","volume":"18","author":"MJ Overman","year":"2017","unstructured":"Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017;18:1182\u201391. https:\/\/doi.org\/10.1016\/S1470-2045(17)30422-9.","journal-title":"Lancet Oncol."},{"key":"1218_CR61","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1200\/JCO.19.00818","volume":"38","author":"NS Azad","year":"2020","unstructured":"Azad NS, Gray RJ, Overman MJ, et al. Nivolumab is effective in mismatch repair-deficient noncolorectal cancers: results from arm Z1D-A subprotocol of the NCI-MATCH (EAY131) study. J Clin Oncol. 2020;38:214\u201322. https:\/\/doi.org\/10.1200\/JCO.19.00818.","journal-title":"J Clin Oncol."},{"key":"1218_CR62","doi-asserted-by":"publisher","unstructured":"Ahn M. MS28.02 Combination IO+IO. J Thorac Oncol 2018;13: S299\u2013S300. https:\/\/doi.org\/10.1016\/j.jtho.2018.08.194.","DOI":"10.1016\/j.jtho.2018.08.194"},{"key":"1218_CR63","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1158\/1538-7445.AM2019-CT183","volume":"79","author":"G Curigliano","year":"2019","unstructured":"Curigliano G, Gelderblom H, Mach N, et al. Abstract CT183: Phase (Ph) I\/II study of MBG453\u00b1 spartalizumab (PDR001) in patients (pts) with advanced malignancies. Cancer Res. 2019;79:13-Supplement CT183. https:\/\/doi.org\/10.1158\/1538-7445.AM2019-CT183.","journal-title":"Cancer Res"},{"key":"1218_CR64","doi-asserted-by":"publisher","first-page":"5009","DOI":"10.1073\/pnas.1100551108","volume":"108","author":"M Jan","year":"2011","unstructured":"Jan M, Chao MP, Cha AC, Alizadeh AA, Gentles AJ, Weissman IL, Majeti R. Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker. Proc Natl Acad Sci USA. 2011;108:5009\u201314. https:\/\/doi.org\/10.1073\/pnas.1100551108.","journal-title":"Proc Natl Acad Sci USA."},{"key":"1218_CR65","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1182\/blood-2019-128178","volume":"134","author":"U Borate","year":"2019","unstructured":"Borate U, Esteve J, Porkka K, et al. Phase Ib study of the anti-TIM-3 antibody MBG453 in combination with decitabine in patients with high-risk myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Blood. 2019;134:570. https:\/\/doi.org\/10.1182\/blood-2019-128178.","journal-title":"Blood"},{"issue":"6","key":"1218_CR66","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s40261-019-00773-w","volume":"39","author":"V Mollica","year":"2019","unstructured":"Mollica V, Di Nunno V, Gatto L, et al. Novel therapeutic approaches and targets currently under evaluation for renal cell carcinoma: waiting for the revolution. Clin Drug Investig. 2019;39(6):503\u201319. https:\/\/doi.org\/10.1007\/s40261-019-00773-w.","journal-title":"Clin Drug Investig."},{"key":"1218_CR67","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s12943-019-1091-2","volume":"18","author":"S Qin","year":"2019","unstructured":"Qin S, Xu L, Yi M, et al. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol Cancer. 2019;18:155. https:\/\/doi.org\/10.1186\/s12943-019-1091-2.","journal-title":"Mol Cancer."}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-022-01218-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-022-01218-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-022-01218-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T11:03:29Z","timestamp":1659092609000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-022-01218-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,26]]},"references-count":67,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["1218"],"URL":"https:\/\/doi.org\/10.1007\/s11912-022-01218-y","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,26]]},"assertion":[{"value":"2 December 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Maria de Miguel has received research funding from MSD, Eli Lilly, PharmaMar, Roche, Novartis, AbbVie, Array BioPharma, Eisai, and Sanofi, and has received compensation for participation on speakers\u2019 bureaus from MSD, Janssen, and Roche. All other authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}